French charity attacks Gilead patent for hepatitis drug

February 10, 2015

French charity Medecins du Monde (MdM) on Tuesday said it was contesting a European patent awarded to a hepatitis drug made by US firm Gilead Sciences, arguing the treatment was too costly.

The organisation—"Doctors of the World"—said it had filed a "brief in opposition" with the European Patent Office (EPO), the Munich-based agency that awards patents covering 40 European countries.

The suit concerns sofosbuvir, a drug marketed as Sovaldi, which is the frontline for hepatitis C.

The goal is to open the way to low-cost generic versions of Solvadi, said MdM's head of French operations, Jean-Francois Corty.

MdM said it expected the outcome of its suit, which it described as the first of its kind in Europe by an NGO, to take up to two years.

Gilead was behaving like "a monopoly," Corty said.

"Gilead is abusing its position as patent-holder to demand intolerably high prices from health-care systems" in Europe and elsewhere, he said.

The cost is so high that the drug is being "rationed," Corty claimed.

MdM said Solvadi was a clearly useful treatment but, in pharmacological terms, it was not so innovative as to deserve patent protection.

Gilead, contacted by AFP, declined to comment on the case.

The suit takes place amid rising concern in Europe about the cost of advanced drugs at a time of budget constraints.

Britain's National Health Service (NHS) last month it would no longer make several cancer treatments available, saying their high cost was not matched by clinical benefits.

A standard 12-week course of Solvadi in France 41,000 euros (46,280 dollars), MdM said.

Treating all patients in France who need the medicine would cost more than five billion euros, or 20 percent of the country's budget, it said.

Explore further: Gilead faces lawsuit over hepatitis C drug pricing

Related Stories

Gilead faces lawsuit over hepatitis C drug pricing

December 10, 2014
Philadelphia's Transportation Authority has filed a lawsuit against Gilead Sciences Inc. over the pricing of its hepatitis C drug.

EU nations join forces against 'exorbitant' hepatitis C drug: France

July 10, 2014
France said Thursday it has joined forces with 13 other European countries to negotiate a lower price for a promising new hepatitis C drug that has drawn controversy for its astronomical cost.

US group seeks to block Gilead drug patent in India

November 24, 2013
A US-based patient rights group said Saturday it has sought to block a bid by California-based Gilead Sciences to obtain an Indian patent for a potentially blockbuster drug to treat hepatitis C.

Aetna picks Gilead Sciences hepatitis C drugs over AbbVie's

January 16, 2015
Insurer Aetna has made new hepatitis C drugs from Gilead Sciences Inc. preferred treatments for customers with the liver-destroying virus.

Medical groups question price of new hep C drug

March 11, 2014
An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care experts, as they consider whether it is worth the $1,000-a-pill price set by manufacturer ...

Gilead to license generic version of Sovaldi (Update)

September 15, 2014
Gilead Sciences has reached a deal with several generic drugmakers to produce a cheaper version of its popular, $1,000-per-pill hepatitis C drug Sovaldi for use in developing countries.

Recommended for you

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.